Middle East Journal of Rehabilitation and Health

Published by: Kowsar

Survival Status and Predictors of Loss to Follow-up Among Adult Patients with Tuberculosis in Public Health Facilities of Sheka Zone, South-West Ethiopia: Facility-Based, Retrospective Cohort Study

Tamrat Shaweno 1 , * , Masrie Getnet 1 and Chaltu Fikru 1
Authors Information
1 Department of Epidemiology, Faculty of Public Health, Institute of Health, Jimma University, Jimma, Ethiopia
Article information
  • Middle East Journal of Rehabilitation and Health: 6 (1); e84068
  • Published Online: January 14, 2019
  • Article Type: Research Article
  • Received: September 8, 2018
  • Accepted: November 30, 2018
  • DOI: 10.5812/mejrh.84068

To Cite: Shaweno T, Getnet M, Fikru C. Survival Status and Predictors of Loss to Follow-up Among Adult Patients with Tuberculosis in Public Health Facilities of Sheka Zone, South-West Ethiopia: Facility-Based, Retrospective Cohort Study, Middle East J Rehabil Health Stud. Online ahead of Print ; 6(1):e84068. doi: 10.5812/mejrh.84068.

Copyright © 2019, Middle East Journal of Rehabilitation and Health Studies. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Akessa GM, Tadesse M, Abebe G. Survival analysis of loss to follow-up treatment among tuberculosis patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia. Int J Statistic Mechanic. 2015;2015:1-7. doi: 10.1155/2015/923025.
  • 2. WHO. Global tuberculosis report 2017. Geneva; 2017.
  • 3. WHO Africa. An epidemiological profile of HIV/AIDS, tuberculosis and Malaria in Sub-Saharan Africa. 2016.
  • 4. Nájera-Ortiz JC, Sánchez-Pérez HJ, Ochoa-Díaz-López H, Leal-Fernández G, Navarro-Giné A. The poor survival among pulmonary tuberculosis patients in Chiapas, Mexico: The case of los altos region. Tuberculosis Res Treat. 2012;2012:1-6. doi: 10.1155/2012/708423.
  • 5. WHO. Use of high burden country lists for TB by WHO in the post. 2015.
  • 6. FMOH; EPHI. Implementation guideline for GeneXpert MTB/RIF assay in Ethiopia. 2014.
  • 7. WHO . Global tuberculosis report 2015. Geneva, Switzerland: World Health Organization; 2015.
  • 8. Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: A systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):219. doi: 10.1186/s12879-017-2323-y. [PubMed: 28320336]. [PubMed Central: PMC5360058].
  • 9. EPHI. First Ethiopian National Population based tuberculosis prevalence survey. Addis Ababa, Ethiopia: Ethiopian Health and Nutrition Research Institute; 2011.
  • 10. Dangisso MH, Datiko DG, Lindtjorn B. Trends of tuberculosis case notification and treatment outcomes in the Sidama Zone, southern Ethiopia: Ten-year retrospective trend analysis in urban-rural settings. PLoS One. 2014;9(12). e114225. doi: 10.1371/journal.pone.0114225. [PubMed: 25460363]. [PubMed Central: PMC4252125].
  • 11. Dangisso MH, Datiko DG, Lindtjorn B. Accessibility to tuberculosis control services and tuberculosis programme performance in southern Ethiopia. Glob Health Action. 2015;8:29443. doi: 10.3402/gha.v8.29443. [PubMed: 26593274]. [PubMed Central: PMC4655224].
  • 12. Datiko DG, Yassin MA, Chekol LT, Kabeto LE, Lindtjorn B. The rate of TB-HIV co-infection depends on the prevalence of HIV infection in a community. BMC Public Health. 2008;8:266. doi: 10.1186/1471-2458-8-266. [PubMed: 18667068]. [PubMed Central: PMC2542368].
  • 13. WHO. Stop TB initiative. Treatment of tuberculosis: Guidelines. Geneva, Switzerland: World Health Organization; 2010.
  • 14. Eshetie S, Gizachew M, Alebel A, van Soolingen D. Tuberculosis treatment outcomes in Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A systematic review and meta-analysis. PLoS One. 2018;13(3). e0194675. doi: 10.1371/journal.pone.0194675. [PubMed: 29554144]. [PubMed Central: PMC5858841].
  • 15. Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: A retrospective cohort study. BMC Res Notes. 2012;5:682. doi: 10.1186/1756-0500-5-682. [PubMed: 23234241]. [PubMed Central: PMC3585495].
  • 16. WHO. Global tuberculosis control. World Health Organization; 2001.
  • 17. Shao Y, Yang D, Xu W, Lu W, Song H, Dai Y, et al. Epidemiology of anti-tuberculosis drug resistance in a chinese population: Current situation and challenges ahead. BMC Public Health. 2011;11(1):110.
  • 18. Russell DG, Barry CE, Flynn JL. Tuberculosis: What we don’t know can, and does, hurt us. Sci. 2010;328(5980):852-6.
  • 19. Orr P. Adherence to tuberculosis care in Canadian Aboriginal Populations, Part 2: A comprehensive approach to fostering adherent behaviour. Int J Circumpolar Health. 2011;70(2):128-40. doi: 10.3402/ijch.v70i2.17810. [PubMed: 21524358].
  • 20. Obermeyer Z, Abbott-Klafter J, Murray CJL. Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS One. 2008;3(3). e1721. doi: 10.1371/journal.pone.0001721. [PubMed: 18320042]. [PubMed Central: PMC2253827].
  • 21. Dye C, Floyd K, Uplekar M. "Global tuberculosis control: Surveillance planning financing" Who report. 2008.
  • 22. WHO. Global tuberculosis control report. Geneva, Switzerland: World Health Organization; 2012.
  • 23. WHO. Definitions and reporting framework for Tuberculosis. World Health Organization; 2013.
  • 24. Federal Democratic Republic of Ethiopia Ministry of Health. Guidelines for clinical and programmatic management of TB, leprosy and TB/HIV in Ethiopia. Addis Ababa, Ethiopia: MOH; 2012.
  • 25. Shaweno D, Shaweno T, Trauer JM, Denholm JT, McBryde ES. Heterogeneity of distribution of tuberculosis in Sheka Zone, Ethiopia: Drivers and temporal trends. Int J Tuberc Lung Dis. 2017;21(1):79-85. doi: 10.5588/ijtld.16.0325. [PubMed: 28157469].
  • 26. Ajagbe OB, Kabir Z, O'Connor T. Survival analysis of adult tuberculosis disease. PLoS One. 2014;9(11). e112838. doi: 10.1371/journal.pone.0112838. [PubMed: 25409024]. [PubMed Central: PMC4237371].
  • 27. Tachfouti N, Slama K, Berraho M, Elfakir S, Benjelloun MC, El Rhazi K, et al. Determinants of tuberculosis treatment default in Morocco: Results from a national cohort study. Pan Afr Med J. 2013;14:121. doi: 10.11604/pamj.2013.14.121.2335. [PubMed: 23734266]. [PubMed Central: PMC3670204].
  • 28. Birlie A, Tesfaw G, Dejene T, Woldemichael K. Time to death and associated factors among tuberculosis patients in Dangila Woreda, Northwest Ethiopia. PLoS One. 2015;10(12). e0144244. doi: 10.1371/journal.pone.0144244. [PubMed: 26669737]. [PubMed Central: PMC4687639].
  • 29. Reves R, Angelo S; CSIS. As Ethiopia moves towards elimination, success requires higher investment. Washington DC; 2016.
  • 30. Berhe G, Enquselassie F, Aseffa A. Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia. BMC Public Health. 2012;12:537. doi: 10.1186/1471-2458-12-537. [PubMed: 22824524]. [PubMed Central: PMC3414747].
  • 31. Beza MG, Wubie MT, Teferi MD, Getahun YS, Bogale SM, Tefera SB. A five years tuberculosis treatment outcome at Kolla Diba Health Center, Dembia district, Northwest Ethiopia: A retrospective crosssectional analysis. J Infect Dis Ther. 2013;1:101.
  • 32. Bao QS, Du YH, Lu CY. Treatment outcome of new pulmonary tuberculosis in Guangzhou, China 1993-2002: A register-based cohort study. BMC Public Health. 2007;7:344. doi: 10.1186/1471-2458-7-344. [PubMed: 18047661]. [PubMed Central: PMC2220000].
  • 33. Addis Z, Birhan W, Alemu A, Mulu A, Ayal G, Negash H. Treatment Outcome of Tuberculosis Patients in Azezo Health Center, North West Ethiopia. Int J Biomed Adv Res. 2013;4(3):167. doi: 10.7439/ijbar.v4i3.300.
  • 34. Mugauri H, Shewade HD, Dlodlo RA, Hove S, Sibanda E. Bacteriologically confirmed pulmonary tuberculosis patients: Loss to follow-up, death and delay before treatment initiation in Bulawayo, Zimbabwe from 2012-2016. Int J Infect Dis. 2018;76:6-13. doi: 10.1016/j.ijid.2018.07.012. [PubMed: 30030177].
  • 35. Aibana O, Slavuckij A, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, et al. Patient predictors of poor drug sensitive tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. Res. 2018;6.
  • 36. FMOH. Tuberculosis progress report. Addis Ababa, Ethiopia; 2011.
  • 37. Agbor AA, Bigna JJ, Billong SC, Tejiokem MC, Ekali GL, Plottel CS, et al. Factors associated with death during tuberculosis treatment of Patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-year hospital-based retrospective cohort study (2006–2013). PLoS One. 2014;9(12). e115211. doi: 10.1371/journal.pone.0115211. [PubMed: 25506830]. [PubMed Central: PMC4266669].
  • 38. Kigozi G, Heunis C, Chikobvu P, Botha S, van Rensburg D. Factors influencing treatment default among tuberculosis patients in a high burden province of South Africa. Int J Infect Dis. 2017;54:95-102. doi: 10.1016/j.ijid.2016.11.407. [PubMed: 27894985].
  • 39. Khan BJ, Kumar AMV, Stewart A, Khan NM, Selvaraj K, Fatima R, et al. Alarming rates of attrition among tuberculosis patients in public-private facilities in Lahore, Pakistan. Public Health Action. 2017;7(2):127-33. doi: 10.5588/pha.17.0001. [PubMed: 28695086]. [PubMed Central: PMC5493094].
  • 40. Pardeshi G. Survival analysis and risk factors for death in tuberculosis patients on directly observed treatment-short course. Indian J Med Sci. 2009;63(5):180-6. doi: 10.4103/0019-5359.53163. [PubMed: 19584488].
  • 41. Moolphate S, Aung MN, Nampaisan O, Nedsuwan S, Kantipong P, Suriyon N, et al. Time of highest tuberculosis death risk and associated factors: An observation of 12 years in Northern Thailand. Int J General Med. 2011;4:181.
  • 42. Amuha MG, Kutyabami P, Kitutu FE, Odoi-Adome R, Kalyango JN. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: Prevalence and associated factors. Africa Health Sci. 2009;9(2).
  • 43. Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: A systematic review. Iran J Public Health. 2015;44(1):1-11. [PubMed: 26060770]. [PubMed Central: PMC4449995].
  • 44. Yende-Zuma N, Naidoo K. The effect of timing of initiation of antiretroviral therapy on loss to follow-up in HIV-tuberculosis coinfected patients in South Africa: An open-label, randomized, controlled trial. J Acquir Immune Defic Syndr. 2016;72(4):430-6. doi: 10.1097/QAI.0000000000000995. [PubMed: 26990824]. [PubMed Central: PMC4927384].
  • 45. Herrero MB, Ramos S, Arrossi S. Determinants of non adherence to tuberculosis treatment in Argentina: Barriers related to access to treatment. Rev Bras Epidemiol. 2015;18(2):287-98. doi: 10.1590/1980-5497201500020001. [PubMed: 26083503].
  • 46. Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: A qualitative study. BMC Public Health. 2010;10:651. doi: 10.1186/1471-2458-10-651. [PubMed: 21029405]. [PubMed Central: PMC2978153].
  • 47. Tupasi TE, Garfin AM, Kurbatova EV, Mangan JM, Orillaza-Chi R, Naval LC, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012-2014. Emerg Infect Dis. 2016;22(3):491-502. doi: 10.3201/eid2203.151788. [PubMed: 26889786]. [PubMed Central: PMC4766881].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments